Ser239
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser239  -  SMAD1 (human)

Site Information
DPMTQDGsQPMDTNM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25546600

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ATM (human) ( 1 )
Kinases, in vitro:
ATM (human) ( 1 )
Treatments:
adriamycin ( 1 ) , caffeine ( 1 )

Downstream Regulation
Effects of modification on SMAD1:
activity, induced ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
apoptosis, induced ( 1 ) , carcinogenesis, inhibited ( 1 ) , DNA repair, induced ( 1 ) , transcription, induced ( 1 )
Induce interaction with:
PPPM1A (human) ( 1 ) , p53 (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
cancer, squamous cell carcinoma ( 1 )

References 

1

Chau JF, et al. (2012) A crucial role for bone morphogenetic protein-Smad1 signalling in the DNA damage response. Nat Commun 3, 836
22588298   Curated Info